5Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress[ J ]. Endocr Rev, 2004,25(4):581-611.
6Hurwitz. Bevacizumab prolongs survival in first-line colorectal cancer (CRC): results of a phase Ⅲ trial of bevacizumab in combination with bolus IFL as first-line therapy in subjects with metastatic CRC[J].ASCO, 2003, 22:3646.
7Hurwitz. bevacizumab Proc. Phase Ⅱ, randomized trial comparing plus fluorouracil(FU)/leucovorin (LV)with FU/LV alone in patients with metastatic colorectal cancer[J]. ASCO, 2003,22:3646.
8HX Chen. Expanding the Clinical Development of Bevacizumab[J].The Oncologist, 2004, 9(Suppl 1):27-35.
9FERNANDO N H, HURWITZ H I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab [J].Oncologist .2004:9(Suppl 1) :11-18.
10HERBERT H, LOUIS F,WILLIAN N, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer[J]. N Engl J Med ,350(23) :2335-2342.
